

<div><div><div><div></div><div>UnitedHealthcare</div><div>Community Plan</div></div></div><div>UnitedHealthcare Community Plan Pharmacy & Therapeutics Committee Minutes</div></div>				
Meeting Date: March 6, 2025 Location: Via conference call/Teams				
Agenda Item	Speaker	Recommendation	Conclusions/ Recommendations	Vote
Meeting called to order		5:01PM EST		
A. Minutes from previous meetings		Review of Minutes from December 12, 2024	Minutes reviewed, approved	Yes
B. Formulary Review - New Drugs		Cobenfy		
		Recommendation: • Non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	9:0
		Olanzapine ODT		
		Recommendation: • Move to preferred across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	9:0
		Risperidone ODT		
		Recommendation: • Move to preferred across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	9:0
		Paliperidone ER		
		Recommendation: • Move to preferred across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	9:0
	Comment:	asked, if a member has had 100-pound weight gain; after trying several antipsychotics, but has not tried lurasidone, would this person be someone who would be approved for Cobenfy?		
		replied each case would be reviewed on a case-by-case basis. The way the criteria is set up now it would be step through 3 preferred atypical antipsychotics, unless there is a extenuating circumstance for that patient specifically.		
		Ebglyss		
		Recommendation: • Non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	9:0
		Adbry		
		Recommendation: • Move to preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	9:0
		Aqneursa		
		Recommendation: • Non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	9:0
		Miplyffa		
		Recommendation: • Non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	9:0
		Legselvi		
		Recommendation: • Non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:0
	Comment:	asked is Legselvi intended to be a lifetime medication.		
		replied the trials were only up to 24 weeks. I think we're expecting long-term use since alopecia areata is a chronic condition, but as far as treatment for the lifetime of the patient that remains to be seen. Monitoring for safety would be important as with any other drug that's new to market, but there is nothing in the package insert about ending therapy after 24 weeks. Additionally, we do see other drugs in this class used long-term so Legselvi would likely be the same.		
		Qlosi		
		Recommendation: • Non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:0
		Hypavzi		
		Recommendation: • Non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:0

		Itovebi		
		Recommendation: • Non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:0
		Revuforj		
		Recommendation: • Non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:0
		Vyalev		
		Recommendation: • Non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:0
		Dhivy		
		Recommendation: • Move to non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:0
		Livdelzi		
		Recommendation: • Non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:0
		Yorvipath		
		Recommendation: • Non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:0
C. Formulary Review - New Formulations		Confirm Review of New Formulations Grid	Yes/No	Yes
		Recommendation: • Erzofti: Non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:0
		Recommendation: • Imkeldi: Non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:0
		Recommendation: • Opipza: Non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:0
		Recommendation: • Zituvimet: Non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:0
		Recommendation: • Zituvimet XR: Non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:0
D. Formulary Review - PDL Modifications		Confirm Review of PDL Modifications Grid	Yes/No	Yes
		Recommendation: • Otulfi pre-filled syringe and vial: Preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:0
		Recommendation: • Yesintek pre-filled syringe and vial: Preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:0
		Recommendation: • Premarin tablet: Move to non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:0
		Recommendation: • Prempro tablet: Move to non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:0
		Recommendation: • Premphase tablet: Move to non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:0
		Recommendation: • Duavee tablet: Move to non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:0
		Recommendation: • Norethindrone acetate/Ethinyl estradiol tablet: Move to preferred across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:0
		Recommendation: • Estradiol/Norethindrone acetate tablet: Move to preferred across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:0
		Recommendation: • Methadone (5mg and 10mg) tablet: Move to preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:0
		Recommendation: • Oxymorphone ER tablet: Move to non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:0
		Recommendation: • Vandazole 0.75% vaginal gel: Move to non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:0
		Recommendation: • Epinephrine 0.3mg (Teva manufacturer) injection: Move to preferred across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:0
		Recommendation: • Epinephrine 0.15mg (Teva manufacturer) injection: Move to preferred across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:0
		Recommendation: • Sevelamer carbonate tablet: Move to preferred across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:0
		Recommendation: • Soliqua: Move to preferred with D2Rx across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:0
		Recommendation: • Sogroya injection: Move to preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:0
		Recommendation: • Norditropin injection: Move to preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:0
		Recommendation: • Unithroid tablet: Move to non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:0
		Recommendation: • Lamotrigine ER tablet: Move to preferred across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:0
		Recommendation: • Levetiracetam ER tablet: Move to preferred across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:0
		Recommendation: • Clobazam tablet and solution: Move to preferred across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:0
		Recommendation: • Lacosamide tablet: Move to preferred across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:0
		Recommendation: • Benznidazole tablet: Move to preferred across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:0
		Recommendation: • Zepbound injection: Move to non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:0
	Comment: ██████████ asked for clarification on the conjugated estrogen being made non-preferred. ██████████ replied, estradiol is already in the preferred position, so there already is an estrogen only product in the preferred position.			

CONFIDENTIAL